Johnson & Johnson Operating Income
Johnson & Johnson (JNJ) reported Operating Income of $5.83 billion for the 3-month period ending 2015-03-29, per its 10-Q filed 2015-05-01.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2015-05-01
- Johnson & Johnson operating income (loss) for the quarter ending 2015-03-29 was $5.83B, a 3.11% increase year-over-year.
- Johnson & Johnson operating income (loss) for the quarter ending 2014-12-28 was $3.01B, a 0.86% decline year-over-year.
- Johnson & Johnson operating income (loss) for the quarter ending 2014-09-28 was $7.05B, a 82.15% increase year-over-year.
- Johnson & Johnson operating income (loss) for the quarter ending 2014-06-29 was $5.88B, a 17.03% increase year-over-year.
- Johnson & Johnson operating income (loss) for fiscal 2014 was $21.59B, a 31.55% increase from fiscal 2013.
- Johnson & Johnson operating income (loss) for fiscal 2013 was $16.41B, a 9.74% increase from fiscal 2012.
- Johnson & Johnson operating income (loss) for fiscal 2012 was $14.96B, a 8.65% increase from fiscal 2012.
- Johnson & Johnson operating income (loss) for fiscal 2012 was $13.77B, a 22.23% decline from fiscal 2011.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2015-03-29 | $5.83B 10-Q · filed 2015-05-01 | $8.84B derived: sum of 2 quarters · filed 2015-05-01 | $15.89B derived: sum of 3 quarters · filed 2015-05-01 | $21.77B derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-12-28 | $3.01B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $10.06B derived: sum of 2 quarters · filed 2015-02-24 | $15.94B derived: sum of 3 quarters · filed 2015-02-24 | $21.59B 10-K · filed 2015-02-24 |
| 2014-09-28 | $7.05B 10-Q · filed 2014-10-30 | $12.93B derived: sum of 2 quarters · filed 2014-10-30 | $18.58B 10-Q · filed 2014-10-30 | $21.62B derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-06-29 | $5.88B 10-Q · filed 2014-08-01 | $11.53B 10-Q · filed 2014-08-01 | $14.56B derived: sum of 3 quarters · filed 2015-05-01 | $18.44B derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-03-30 | $5.65B 10-Q · filed 2015-05-01 | $8.69B derived: sum of 2 quarters · filed 2015-05-01 | $12.56B derived: sum of 3 quarters · filed 2015-05-01 | $17.58B derived: sum of 4 quarters · filed 2015-05-01 |
| 2013-12-29 | $3.04B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $6.91B derived: sum of 2 quarters · filed 2015-02-24 | $11.93B derived: sum of 3 quarters · filed 2015-02-24 | $16.41B 10-K · filed 2015-02-24 |
| 2013-09-29 | $3.87B 10-Q · filed 2014-10-30 | $8.89B derived: sum of 2 quarters · filed 2014-10-30 | $13.37B 10-Q · filed 2014-10-30 | $16.72B derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $5.02B 10-Q · filed 2014-08-01 | $9.50B 10-Q · filed 2014-08-01 | $12.84B derived: sum of 3 quarters · filed 2015-02-24 | $16.67B derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-03-31 | $4.48B 10-Q · filed 2014-05-02 | $7.82B derived: sum of 2 quarters · filed 2015-02-24 | $11.65B derived: sum of 3 quarters · filed 2015-02-24 | $14.31B derived: sum of 4 quarters · filed 2015-02-24 |
| 2012-12-30 | $3.34B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $7.17B derived: sum of 2 quarters · filed 2015-02-24 | $9.82B derived: sum of 3 quarters · filed 2015-02-24 | $14.96B 10-K · filed 2015-02-24 |
| 2012-09-30 | $3.83B 10-Q · filed 2013-11-04 | $6.48B derived: sum of 2 quarters · filed 2013-11-04 | $11.61B 10-Q · filed 2013-11-04 | $12.46B derived: sum of 4 quarters · filed 2014-02-21 |
| 2012-07-01 | $2.66B 10-Q · filed 2013-08-01 | $7.79B 10-Q · filed 2013-08-01 | $8.64B derived: sum of 3 quarters · filed 2014-02-21 | $13.29B derived: sum of 4 quarters · filed 2014-02-21 |
| 2012-04-01 | $5.13B 10-Q · filed 2013-05-03 | $5.98B derived: sum of 2 quarters · filed 2014-02-21 | $10.63B derived: sum of 3 quarters · filed 2014-02-21 | $14.17B derived: sum of 4 quarters · filed 2014-02-21 |
| 2012-01-01 | $852.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $5.50B derived: sum of 2 quarters · filed 2014-02-21 | $9.04B derived: sum of 3 quarters · filed 2014-02-21 | $13.77B 10-K · filed 2014-02-21 |
| 2011-10-02 | $4.65B 10-Q · filed 2012-11-09 | $8.19B derived: sum of 2 quarters · filed 2012-11-09 | $12.91B 10-Q · filed 2012-11-09 | $15.42B derived: sum of 4 quarters · filed 2013-02-22 |
| 2011-07-03 | $3.54B 10-Q · filed 2012-08-02 | $8.26B 10-Q · filed 2012-08-02 | $10.77B derived: sum of 3 quarters · filed 2013-02-22 | $15.13B derived: sum of 4 quarters · filed 2013-02-22 |
| 2011-04-03 | $4.73B 10-Q · filed 2012-05-07 | $7.23B derived: sum of 2 quarters · filed 2013-02-22 | $11.59B derived: sum of 3 quarters · filed 2013-02-22 | $15.97B derived: sum of 4 quarters · filed 2013-02-22 |
| 2011-01-02 | $2.50B derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-22 | $6.87B derived: sum of 2 quarters · filed 2013-02-22 | $11.24B derived: sum of 3 quarters · filed 2013-02-22 | $17.70B 10-K · filed 2013-02-22 |
| 2010-10-03 | $4.36B 10-Q · filed 2011-11-08 | $8.74B derived: sum of 2 quarters · filed 2011-11-08 | $15.20B 10-Q · filed 2011-11-08 | |
| 2010-07-04 | $4.38B 10-Q · filed 2011-08-09 | $10.84B 10-Q · filed 2011-08-09 | ||
| 2010-01-03 | $16.58B 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |